Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer
Target Agent(s) Phase Summary Identifier mTOR Everolimus (Docetaxel) (Bevacizumab) Ib/II Dose-finding/efficacy study; Docetaxel + everolimus + bevacizumab in metastatic CRPC NCT00574769 mTOR Temsirolimus (Bevacizumab) I/II Dose-finding/efficacy study; Temsirolimus + bevacizumab in metastatic CRPC NCT01083368 mTOR Everolimus…